Description

5-(Morpholinomethyl)-3-[(5-Nitrofurfurylidene)Amino]Oxazolidin-2-One [R-(R*,R*)]-Tartrate is a specialized chiral organic compound that serves as a critical intermediate in advanced pharmaceutical synthesis. Its complex molecular architecture, featuring morpholine, nitrofuran, and oxazolidinone moieties, makes it a valuable building block for developing novel therapeutic agents with targeted biological activity. This high-purity intermediate is essential for research and development chemists and manufacturers in the pharmaceutical and agrochemical industries, particularly those focused on creating new anti-infective and antimicrobial compounds.

Application

• Pharmaceutical Intermediate: A key chiral synthon in the research and development of new antibacterial and antimicrobial drug candidates, particularly those targeting resistant strains.
• Antibiotic Research: Serves as a precursor in the synthesis of novel nitrofuran and oxazolidinone-class antibiotics, leveraging its unique chemical structure for structure-activity relationship (SAR) studies.
• Agrochemical Development: Used in the synthesis of experimental fungicides or bactericides for crop protection, exploiting the bioactive nitrofurfurylidene component.
• Chemical Biology Probes: Employed in academic and industrial research to develop molecular probes for studying bacterial enzyme mechanisms and inhibition.
• Process Chemistry: Utilized in scale-up and optimization studies for the commercial production of complex active pharmaceutical ingredients (APIs).
• Chiral Pool Synthesis: Provides a source of defined stereochemistry ([R-(R*,R*)]) for the asymmetric synthesis of other valuable chiral molecules.

Basic Information

Item	Detail
Product Name	5-(Morpholinomethyl)-3-[(5-Nitrofurfurylidene)Amino]Oxazolidin-2-One [R-(R*,R*)]-Tartrate
CAS No.	71662-11-8
Molecular Formula	C19H24N4O11
Molecular Weight	484.42 g/mol
Synonyms	(R,R)-5-(Morpholinomethyl)-3-[(5-nitrofurfurylidene)amino]-2-oxazolidinone tartrate; 5-(Morpholinomethyl)-3-[(5-nitrofurfurylidene)amino]-2-oxazolidinone (R,R)-tartrate; (R,R)-Furaltadone tartrate intermediate; Furaltadone related compound tartrate salt; (R,R)-3-((5-Nitro-2-furyl)methylene)amino-5-(morpholinomethyl)-2-oxazolidinone tartrate; (R,R)-5-Morpholinomethyl-3-[(5-nitrofurfurylidene)amino]-2-oxazolidinone L-(+)-tartrate
EINECS	Contact for details

Quality Control

Our production of this advanced intermediate adheres to strict quality management systems. Every batch undergoes comprehensive analytical testing, including chiral purity verification, to ensure it meets the exacting standards required for pharmaceutical R&D and cGMP manufacturing. Certificates of Analysis (COA) are provided with each shipment, detailing key parameters such as enantiomeric excess, assay, and impurity profiles. We support compliance with global regulatory frameworks, including REACH and FDA guidelines for drug substance intermediates.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated place at a controlled room temperature (15-25°C). This compound is hygroscopic (moisture-sensitive) and light-sensitive; therefore, containers must be kept tightly sealed and in original packaging until use to prevent degradation. Keep away from incompatible materials.

Specification

Item	Specification
Appearance	Yellow to orange crystalline powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Chiral Purity (HPLC)	≥ 99.0% ee ([R-(R*,R*)] isomer)
Loss on Drying	≤ 1.0%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 20 ppm
Related Substances (HPLC)	Total impurities ≤ 2.0%; Any single impurity ≤ 0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.